Azurity Archives
News and events as they happenAzurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity
Woburn, MA – November 17, 2025 – Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies.
Azurity Pharmaceuticals Announces FDA Approval of JAVADINTM (clonidine hydrochloride) Oral Solution
Woburn, MA—October 24, 2025—Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved JavadinTM (clonidine hydrochloride) oral solution, the only FDA-approved, immediate-release, ready-to-use oral liquid clonidine formulation for the treatment of hypertension in adult patients to lower blood pressure. Lowering blood pressure has been shown to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
ACA Pharma Named Exclusive Distributor for Feraheme® in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore
New York, NY — October 23, 2025— ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have signed an exclusive distribution partnership agreement for ACA Pharma to commercialize Feraheme® (ferumoxytol injection) across Hong Kong, Macau, the Greater Bay Area (GBA), Mainland China, and Singapore.
Azurity Pharmaceuticals Announces the FDA Approval of FerabrightTM (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the Brain
Woburn, MA — October 17, 2025 — Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ferabright™ (ferumoxytol injection), the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.1
